Markus Pfirrmann

TL;DR: A new prognostic scoring system for estimating survival of patients with CML treated with interferon alfa has been developed and validated through use of a large dataset and the ability of the new scoring system to discriminate risk groups was confirmed.

TL;DR: A new prognostic score that is superior to the Sokal and Euro scores both in its prognostic ability and in its simplicity is described, which can be used to identify CML patients with significantly lower probabilities of responding to therapy and survival, thus alerting physicians to those patients who require closer observation and early intervention.

TL;DR: In this paper, a prospective, non-randomised trial was conducted at 61 European centres in 11 countries to investigate the impact of stopping TKI therapy on the survival of patients with chronic myeloid leukaemia.

TL;DR: Treatment optimization is recommended for pts missing these landmarks and early prediction of prognosis on imatinib is desirable to assure favorable survival or otherwise consider the use of a second-generation tyrosine kinase inhibitor (TKI).

TL;DR: Early high-dose therapy followed by rapid adaptation to good tolerability increases the rate of major molecular remission (MMR) at 12 months, and achievement of MMR by month 12 is directly associated with improved survival.